Atossa Therapeutics Inc (ATOS) reports reduced operating expenses and promising developments in its lead program, Z-endoxifen, while maintaining a strong cash position.

And we're going to take some Q&A after that. So with the highlights ... And this is a normal situation with the instability that was with Atos during the year of 2024. If we deep dive between ...

Atos, a global systems integrator and solution provider with a focus on cloud and digital transformation and a large managed security services practice, Tuesday unveiled a plan to potentially ...

Atos, which owns the supercomputers essential to France's nuclear deterrent, will hold a capital markets day event in May to announce its new strategy. ($1 = 0.9242 euros) ...

Atos' first half of 2023 isn't looking bright after its Q2 financial report which highlighted a plummeting operating income and caused shares price to drop by 20 per cent. The report showed operating ...

Atos has posted an uplift in revenues for the first quarter of 2023, a recovery from its Q1 loss in 2022 as the company credits its strategic transformation for the growth. Group revenues totalled ...

The sale of its Tech Foundations managed services business, which would include the Atos brand name, would if it closes as planned leave a stand-alone digital transformation company known as ...

Regional revenue declines raise concerns. Atos reported a full-year 2024 revenue of €9.6 billion, marking a 5.4% organic decline. Despite the revenue drop, the company’s operating margin stood ...